BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
BioVie (OTCQB:BIVI) reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
As quoted in the press release:
“BioVie has achieved key milestones and significantly advanced the business plan,” said CEO Jonathan Adams. “We will continue taking important steps toward BIV201 approval and commercialization and building company value for our shareholders.” BioVie is an emerging leader in the development of drug therapies for ascites and other life-threatening complications of advanced liver cirrhosis. The market potential for a therapy that can address these serious unmet medical needs is substantial, potentially exceeding $1 billion.
The Company has received FDA clearance to begin a mid-stage (Phase 2a) clinical trial in the US administering BIV201 to patients with refractory ascites, and dosing of the first patient is very close. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis, but is not available in the US or Japan.
Click here to read the full press release.
Source: www.marketwired.com
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1927.31 | -0.01 | |
Silver | 23.44 | -0.23 | |
Copper | 4.17 | -0.05 | |
Palladium | 1713.17 | 0.00 | |
Platinum | 1087.26 | 0.00 | |
Oil | 78.87 | 0.00 | |
Heating Oil | 3.12 | -0.03 | |
Natural Gas | 2.71 | +0.02 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured Pharmaceutical Investing Stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.